Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (171-180 of 266) with videos related to

Pageof 27
Sort By:
Parkinson'S Disease|May 7, 2014
Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended releaseRobert A Hauser, Mark Forrest Gordon, Yoshikuni Mizuno, et al.
Brain : a Journal of Neurology|February 5, 2013
Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viabilityGiulia Cisbani, Thomas B Freeman, Denis Soulet, et al.
Parkinsonism & Related Disorders|September 24, 2013
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's diseaseRajesh Pahwa, Kelly E Lyons, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2010
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's diseaseJuliana Bronzova, Cristina Sampaio, Robert A Hauser, et al.
Clinical Neuropharmacology|August 2, 2008
Caffeine and progression of Parkinson diseaseDavid K Simon, Christopher J Swearingen, Robert A Hauser, et al.
Parkinsonism & Related Disorders|November 1, 2020
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's diseaseEric S Farbman, Cheryl H Waters, Peter A LeWitt, et al.
Journal of Parkinson'S Disease|January 14, 2020
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's DiseaseCaroline M Tanner, Rajesh Pahwa, Robert A Hauser, et al.
Clinical Parkinsonism & Related Disorders|August 23, 2024
Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson's disease experiencing OFF episodes: A modified Delphi panelStuart H Isaacson, Richard Dewey, Robert A Hauser, et al.
CNS Spectrums|November 20, 2020
Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practiceRobert A Hauser, Jonathan M Meyer, Stewart A Factor, et al.
Plos One|April 14, 2021
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Pageof 27

Showing results (171-180 of 266) with videos related to

Sort By:
Pageof 27
Parkinson'S Disease|May 7, 2014
Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended releaseRobert A Hauser, Mark Forrest Gordon, Yoshikuni Mizuno, et al.
Brain : a Journal of Neurology|February 5, 2013
Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viabilityGiulia Cisbani, Thomas B Freeman, Denis Soulet, et al.
Parkinsonism & Related Disorders|September 24, 2013
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's diseaseRajesh Pahwa, Kelly E Lyons, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2010
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's diseaseJuliana Bronzova, Cristina Sampaio, Robert A Hauser, et al.
Clinical Neuropharmacology|August 2, 2008
Caffeine and progression of Parkinson diseaseDavid K Simon, Christopher J Swearingen, Robert A Hauser, et al.
Parkinsonism & Related Disorders|November 1, 2020
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's diseaseEric S Farbman, Cheryl H Waters, Peter A LeWitt, et al.
Journal of Parkinson'S Disease|January 14, 2020
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's DiseaseCaroline M Tanner, Rajesh Pahwa, Robert A Hauser, et al.
Clinical Parkinsonism & Related Disorders|August 23, 2024
Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson's disease experiencing OFF episodes: A modified Delphi panelStuart H Isaacson, Richard Dewey, Robert A Hauser, et al.
CNS Spectrums|November 20, 2020
Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practiceRobert A Hauser, Jonathan M Meyer, Stewart A Factor, et al.
Plos One|April 14, 2021
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Pageof 27